Point72 Asia (Singapore) Pte. Ltd. Lineage Cell Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $563 Billion
- Q2 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 111,241 shares of LCTX stock, worth $209,133. This represents 0.02% of its overall portfolio holdings.
Number of Shares
111,241Holding current value
$209,133% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
136Shares Held
99.2MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$93.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.9 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.1 Million6.02% of portfolio
-
Comerica Bank4.6MShares$8.65 Million0.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $319M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...